Armand Dabbon v. HHS - Tdap, Guillain-Barre Syndrome (2021)
Case summary [AI summaries can sometimes make mistakes]
Armand Dabbon filed a petition for compensation under the National Vaccine Injury Compensation Program on November 21, 2018, alleging he developed Guillain-Barre Syndrome (GBS) after receiving a tetanus-diphtheria-acellular pertussis (Tdap) vaccination on February 27, 2017. The respondent denied that the Tdap vaccine caused Mr.
Dabbon's GBS, any other injury, or his current condition. Despite the respondent's denial, the parties reached a joint stipulation to settle the case.
The stipulation, filed on March 16, 2021, outlined the settlement terms. The respondent agreed to issue a payment of $105,000.00 to Mr.
Dabbon as compensation for all damages available under the program. Special Master Mindy Michaels Roth adopted the stipulation and awarded the compensation on March 16, 2021.
The decision was filed on March 16, 2021. Petitioner counsel was Leah Durant, Esq., of the Law Offices of Leah V.
Durant, PLLC. Respondent counsel was Mary Holmes, Esq., of the US Department of Justice.
The public decision does not describe the onset of symptoms, specific clinical details, diagnostic tests, treatments, or expert witnesses. The decision is unpublished but will be posted on the Court of Federal Claims' website.
Theory of causation
Petitioner Armand Dabbon alleged Guillain-Barre Syndrome (GBS) following a Tdap vaccination on February 27, 2017. Respondent denied causation. The parties reached a joint stipulation to settle the case, agreeing to a lump sum payment of $105,000.00 to petitioner for all damages. Special Master Mindy Michaels Roth adopted the stipulation and awarded compensation on March 16, 2021. The public decision does not detail the specific theory of causation, mechanism of injury, expert testimony, or the basis for the settlement. Petitioner was represented by Leah Durant, Esq., and respondent by Mary Holmes, Esq.
Source PDFs
USCOURTS-cofc-1_18-vv-01796